302 related articles for article (PubMed ID: 35978142)
1. Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model.
Siemionow M; Brodowska S; Langa P; Zalants K; Kozlowska K; Grau-Kazmierczak W; Heydemann A
Arch Immunol Ther Exp (Warsz); 2022 Aug; 70(1):20. PubMed ID: 35978142
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
[TBL] [Abstract][Full Text] [Related]
3. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
[TBL] [Abstract][Full Text] [Related]
4. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
[TBL] [Abstract][Full Text] [Related]
5. Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.
Siemionow M; Malik M; Langa P; Cwykiel J; Brodowska S; Heydemann A
Stem Cell Rev Rep; 2019 Dec; 15(6):827-841. PubMed ID: 31612351
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model.
Siemionow M; Budzynska K; Zalants K; Langa P; Brodowska S; Siemionow K; Heydemann A
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540201
[TBL] [Abstract][Full Text] [Related]
7. Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.
Siemionow M; Cwykiel J; Heydemann A; Garcia J; Marchese E; Siemionow K; Szilagyi E
Stem Cell Rev Rep; 2018 Jun; 14(3):370-384. PubMed ID: 29546607
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration.
Budzynska K; Siemionow M; Stawarz K; Chambily L; Siemionow K
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785982
[TBL] [Abstract][Full Text] [Related]
9. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
[TBL] [Abstract][Full Text] [Related]
10. Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
Heydemann A; Bieganski G; Wachowiak J; Czarnota J; Niezgoda A; Siemionow K; Ziemiecka A; Sikorska MH; Bozyk K; Tullius SG; Siemionow M
Stem Cell Rev Rep; 2023 Jul; 19(5):1340-1359. PubMed ID: 37000376
[TBL] [Abstract][Full Text] [Related]
11. Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in
Malik M; Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
Postepy Kardiol Interwencyjnej; 2022 Dec; 18(4):399-406. PubMed ID: 36967847
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
Niezgoda A; Biegański G; Wachowiak J; Czarnota J; Siemionow K; Heydemann A; Ziemiecka A; Sikorska MH; Bożyk K; Siemionow M
Arch Immunol Ther Exp (Warsz); 2023 Nov; 71(1):24. PubMed ID: 37999748
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
Siemionow M; Biegański G; Niezgoda A; Wachowiak J; Czarnota J; Siemionow K; Ziemiecka A; Sikorska MH; Bożyk K; Heydemann A
Stem Cell Rev Rep; 2023 Nov; 19(8):2724-2740. PubMed ID: 37707670
[TBL] [Abstract][Full Text] [Related]
14. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the
Potter RA; Griffin DA; Heller KN; Peterson EL; Clark EK; Mendell JR; Rodino-Klapac LR
Hum Gene Ther; 2021 Apr; 32(7-8):375-389. PubMed ID: 33397205
[TBL] [Abstract][Full Text] [Related]
15. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
[TBL] [Abstract][Full Text] [Related]
16. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
17. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy.
Albini S; Palmieri L; Dubois A; Bourg N; Lostal W; Richard I
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511179
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease.
Eren SA; Tastan C; Karadeniz KB; Turan RD; Cakirsoy D; Kancagi DD; Yilmaz SU; Oztatlici M; Oztatlici H; Ozer S; Tumentemur G; Baykal AT; Ovali E
Curr Gene Ther; 2023; 23(4):304-315. PubMed ID: 37032509
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins.
Bonuccelli G; Sotgia F; Schubert W; Park DS; Frank PG; Woodman SE; Insabato L; Cammer M; Minetti C; Lisanti MP
Am J Pathol; 2003 Oct; 163(4):1663-75. PubMed ID: 14507673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
